Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Earnings for Mirum Pharmaceuticals, Inc. (MIRM)
Earnings in 2023 (TTM): $-162,424,000
According to Mirum Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-162,424,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Mirum Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-162,424,000 | $-163,415,000 |
| 2022 | $-142,071,000 | $-135,665,000 |
| 2021 | $-83,951,000 | $-83,988,000 |
| 2020 | $-103,264,000 | $-103,270,000 |
| 2019 | $-52,532,000 | $-52,553,000 |
| 2018 | $-17,348,000 | $-17,348,000 |